The round was led by Venrock with participation from Foresite Capital and Paladin Capital as well as existing investors NanoDimension and Spruce/MLS.
The company intends to use the funds to accelerate its development efforts to bring its ForgeCraft™ to scientists worldwide.
Led by Kevin Ness, CEO, Muse bio is advancing genome engineering and synthetic biology technology (ForgeCraft) which combines computer aided forward design software package, a proprietary benchtop biofoundry, and custom reagents to enable researchers and production scientists to rapidly explorate the genetic landscape at scale and accelerate their work.
FinSMEs
28/02/2017